
NASDAQHealthcareBiotechnology
最新資料
US$0.797
−US$0.0859 · -9.73%
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
前收盤價
US$0.797
−US$0.0859 · -9.73%
盤中時間採用ET。市場資料可能有所延遲。
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
日內區間
目前US$0.797
52週區間
目前US$0.797
第三方分析師預期可能變動,並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年6月24日 | 1:30 | — | — |
股票分割 | 2022年7月22日 | 1:10 | — | — |
股票分割 | 2018年7月17日 | 1:10 | — | — |
股票分割 | 2016年3月7日 | 1:10 | — | — |
股票分割 | 2014年6月16日 | 1:20 | — | — |
股票分割 | 2011年4月11日 | 1:153 | — | — |
已生效 2025年6月24日
1:30
已生效 2022年7月22日
1:10
已生效 2018年7月17日
1:10
已生效 2016年3月7日
1:10
已生效 2014年6月16日
1:20
已生效 2011年4月11日
1:153
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。